Maverick Capital Ltd. boosted its position in Shire PLC (NASDAQ:SHPG) by 19.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,942,087 shares of the biopharmaceutical company’s stock after buying an additional 322,610 shares during the period. Shire PLC makes up about 4.0% of Maverick Capital Ltd.’s holdings, making the stock its 8th biggest position. Maverick Capital Ltd.’s holdings in Shire PLC were worth $320,969,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of SHPG. Hartford Financial Management Inc. grew its position in Shire PLC by 5.4% in the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 32 shares during the last quarter. YorkBridge Wealth Partners LLC grew its position in Shire PLC by 81.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 317 shares during the last quarter. Pacer Advisors Inc. purchased a new position in Shire PLC in the 2nd quarter valued at $171,000. Stephens Inc. AR purchased a new position in Shire PLC in the 1st quarter valued at $179,000. Finally, Quantbot Technologies LP purchased a new position in Shire PLC in the 1st quarter valued at $182,000. Hedge funds and other institutional investors own 19.28% of the company’s stock.

SHPG has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Shire PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub lowered shares of Shire PLC from a “hold” rating to a “sell” rating in a research report on Saturday, July 1st. ValuEngine lowered shares of Shire PLC from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $222.00 price objective on shares of Shire PLC in a research report on Thursday, September 14th. Finally, BTIG Research restated a “buy” rating and set a $242.00 target price on shares of Shire PLC in a research report on Monday, July 17th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $220.91.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/shire-plc-shpg-is-maverick-capital-ltd-s-8th-largest-position/1610321.html.

Shire PLC (SHPG) traded up 0.238% during midday trading on Thursday, hitting $153.505. 367,493 shares of the company traded hands. Shire PLC has a 12-month low of $139.36 and a 12-month high of $198.58.

Shire PLC (NASDAQ:SHPG) last announced its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. Equities analysts predict that Shire PLC will post $14.93 EPS for the current year.

The company also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be paid a dividend of $0.1527 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a yield of 0.21%. Shire PLC’s dividend payout ratio is currently 41.07%.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.